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Edited by Eric R. Fearon
The role of mitochondria in cancer continues to be debated, and
whether exploitation of mitochondrial functions is a general hall-
mark of malignancy or a tumor- or context-specific response is still
unknown. Using a variety of cancer cell lines and several technical
approaches, including siRNA-mediated gene silencing, ChIP
assays, global metabolomics and focused metabolite analyses, bio-
energetics, and cell viability assays, we show that two oncogenic
Myc proteins, c-Myc and N-Myc, transcriptionally control the
expression of the mitochondrial chaperone TNFR-associated pro-
tein-1 (TRAP1) in cancer. In turn, this Myc-mediated regulation
preserved the folding and function of mitochondrial oxidative
phosphorylation (OXPHOS) complex II and IV subunits, damp-
ened reactive oxygen species production, and enabled oxidative
bioenergetics in tumor cells. Of note, we found that genetic or
pharmacological targeting of this pathway shuts off tumor cell
motility and invasion, kills Myc-expressing cells in a TRAP1-de-
pendent manner, and suppresses primary and metastatic tumor
growth in vivo. We conclude that exploitation of mitochondrial
functions is a general trait of tumorigenesis and that this reliance
of cancer cells on mitochondrial OXPHOS pathways could offer an
actionable therapeutic target in the clinic.
A hallmark of cancer is the reprogramming of cellular metabo-
lism (1). Much work has been devoted to the preferential utiliza-
tion of glycolysis by tumor cells, even when oxygen is present (2),
and its impact on cancer progression (3). However, we now know
that mitochondria remain functional in most malignancies and
that oxidative bioenergetics fuel important tumor traits (4),
including metastasis (5, 6). Although both metabolic states are
likely to coexist during tumor growth (7), a direct, mechanistic link
between oncogenic signaling and mitochondrial functions has not
been determined, and the question of how general is the exploita-
tion of mitochondria in cancer (4) has remained unanswered.
In this context, Myc proteins comprise a family of ubiqui-
tous, transforming oncogenes (8) that are amplified, deregu-
lated, or translocated in most human cancers (9). Oncogenic
Myc drives a plethora of transcriptional and nontranscriptional
responses that promote tumor growth and proliferation (10),
linked to worse disease outcome in the clinic (11). Although the
Myc target gene(s) in tumor progression has not been com-
pletely elucidated, and controversy still exists about the
requirements of Myc-directed gene expression (12), this path-
way connects to multiple aspects of tumor metabolism (13),
including mitochondrial functions (14, 15).
In this study, we investigate a role of oncogenic Myc in
exploiting mitochondria for cancer progression.
Results and discussion
Myc regulation of mitochondrial metabolism
Oncogenic Myc drives aggressive and metastatic prostate can-
cer (16). Therefore, we began this study by conducting a global
metabolomics screening (5,000 metabolites, first metabolomic
screen) in prostate adenocarcinoma PC3 cells transfected with
nontargeted siRNA or Myc-directed siRNA. Loss of Myc in these
conditions down-regulated several metabolic clusters (clusters 9
and 4) (Fig. S1A). Bioinformatics analysis of this dataset (Fig. S1B)
demonstrated that Myc loss reduced the levels of purine (AMP
21.9-fold; ADP21.7-fold; GDP21.9-fold; GTP21.3-fold) and
pyrimidine (UDP22.6-fold; UTP21.6-fold) bases, TCA2 cycle
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intermediates (citrate 21.7-fold, malate 21.4-fold; cis-aconitic
acid21.7-fold; succinate21.3-fold), and catabolites (urea21.5-
fold; creatinine21.3-fold) (Fig. 1A, Fig. S1B). A second focused
metabolomics screen of 300 metabolites gave similar results
(Fig. S1B), as Myc silencing in PC3 cells reduced the levels of oxi-
dative phosphorylation and TCA cycle biochemicals, along with
metabolites involved in purine and pyrimidine biosynthetic path-
ways and amino acid levels (Fig. 1A and Fig. S1B). Conversely, Myc
knockdown did not affect glutamine levels in PC3 cells (13), sug-
gesting tumor-specific differences in metabolic reprogramming.
Consistent with these data, Myc-silenced PC3 cells exhibited
decreased oxygen consumption rates (OCR) (Fig. S1C) and overall
reduced oxygen consumption (Fig. 1B). Together with lower glu-
cose utilization (Fig. S1D), decreased lactate generation (Fig. S1E),
and reduced extracellular acidification rates (ECAR) (Fig. S1F),
these cells showed diminished ATP production, compared with
control transfectants (Fig. 1C).
Control of mitochondrial protein folding by Myc
Next, we looked at the mechanism(s) of Myc regulation of
oxidative phosphorylation. We found that Myc silencing in PC3
cells caused the accumulation of detergent-insoluble subunits,
i.e. misfolded oxidative phosphorylation complex subunits,
including succinate dehydrogenase B (SDHB, complex II) and
cytochrome c oxidase II (CoxII, complex IV) (Fig. 1, D and E).
Other oxidative phosphorylation subunits, ubiquinol-cyto-
chrome c reductase core protein 2 (UQCRC2, complex III) or
ATP synthase F1 subunit (ATP5A, complex V), were unaf-
fected (Fig. S2A). Consistent with these results, Myc knock-
down resulted in reduced mitochondrial complex II and com-
plex IV activity, compared with control transfectants (Fig. 1F;
Fig. S2B). Instead, complex I activity was unchanged in control
or Myc-silenced cells (Fig. S2, C and D). In line with the defects
of oxidative bioenergetics, Myc loss was accompanied by
increased production of mitochondrial ROS (Fig. S2E), hyper-
oxidation of peroxiredoxin-3 (Prx3) (Fig. S2F), a marker of oxi-
dative stress, and phosphorylation of the energy sensor, AMPK
(Thr-172), indicative of nutrient deprivation (Fig. S2F).
Mitochondrial chaperone TRAP1 is a novel Myc target gene
Previous studies have shown that SDHB protein folding
requires the activity of the mitochondrial Hsp90-like chaper-
one, TNFR-associated protein-1 (TRAP1) (17). Analysis of
ChIP-Seq tracks demonstrated time-dependent accumulation
of Myc at the TRAP1 promoter in Burkitt’s lymphoma P493
cells as well as neuroblastoma BE2C, Kelly, and NGP cell lines
(Fig. 2A). Consistent with this, Myc bound to the promoter of
TRAP1, as well as NPM1, a known Myc target gene, by ChIP in
Figure 1. Myc regulation of mitochondrial bioenergetics and protein folding. A, networks of associations between metabolites significantly affected by
siRNA silencing of Myc in PC3 cells. The metabolites shown are concordantly modulated in a global metabolomics screen (5,000 metabolites) and a focused
metabolite analysis (300 metabolites). B and C, PC3 cells transfected with control nontargeting siRNA (siCtrl) or Myc-directed siRNA (siMyc) were analyzed for
total oxygen consumption (B) or ATP production (C). Mean  S.D. (n  3–7). ***, p  0.0001. D, PC3 cells were transfected as in B, and detergent (CHAPS)-
insoluble proteins were analyzed. The position of the oxidative phosphorylation complex (C) subunits is indicated. Citrate synthase (CS) and oxidative
phosphorylation complex II subunit, SDHD, were used as controls. E, conditions are as in C, and protein bands corresponding to complex II subunit, SDHB, or
complex IV subunit, CoxII, were quantified by densitometry (n  2). F, PC3 cells transfected as in B were analyzed for citrate synthase–normalized mitochondrial
oxidative phosphorylation complex II (top) or complex IV (bottom) activity. Representative tracings out of three independent experiments are shown.
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P493 or PC3 cells, in a reaction abolished by siRNA knockdown
of Myc (Fig. 2B). As a result, Myc silencing reduced the expres-
sion of TRAP1 mRNA (Fig. S3A) and protein (Fig. S3B) in var-
ious tumor cell types. Bioinformatics analysis of four indepen-
dent cancer cell line data bases demonstrated that high levels of
Myc strongly correlated (p  2.6  1020– 6.1  10117) with
TRAP1 expression (Fig. S3C), reinforcing the generality of this
response across genetically disparate tumors.
We next asked whether the Myc homolog, N-Myc, also reg-
ulated TRAP1 in the model of neuroblastoma (Fig. 2A). Condi-
tional silencing of N-Myc in neuroblastoma SHEP21 cells
reduced TRAP1 mRNA (Fig. S4A) and protein expression (Fig.
S4B). Conversely, 4OHT-regulated induction of N-Myc in
SHEP or SKNAS cells increased TRAP1 mRNA (Fig. S4C) and
protein levels (Fig. S4B). Sequence analysis of a human TRAP1
locus revealed the presence of putative c-Myc- and N-Myc–
binding sites within 1.4 kb of the first ATG (Fig. S4D). Trans-
fection of this TRAP1 promoter region upstream of a luciferase
reporter gene (TRAP1-Luc) produced luciferase activity in PC3
or P493 cells, in a response abolished by siRNA knockdown of
Myc (Fig. S4E). In addition, mutagenesis of a putative Myc-
binding site at position 60 abolished TRAP1-Luc luciferase
activity in control and Myc-knockdown PC3 cells (Fig. S4F).
Next, we asked whether TRAP1 was required for mitochon-
drial bioenergetics in Myc-expressing tumors. We found that
re-expression of non-siRNA–inhibitable TRAP1 in Myc
knockdown cells rescued the defect of OCR (Fig. 2C) and cor-
rected basal respiration in these settings (Fig. 2D). Consistent
with improved bioenergetics, reconstitution with TRAP1
restored ATP production in Myc knockdown cells (Fig. 2E) and
reversed the expression of markers of cellular starvation
(AMPK phosphorylation) and oxidative stress (Prx3 hyperoxi-
dation) (Fig. 2F). As a prerequisite of these responses, re-ex-
pression of TRAP1 in Myc knockdown PC3 cells corrected the
folding of SDHB (complex II) and CoxII (complex IV) subunits
(Fig. 2G; Fig. S5A), restoring complex II (Fig. S5, B and C) and
complex IV (Fig. S5, D and E) activity, quantitatively compara-
ble with control transfectants.
Myc–TRAP1 signaling fuels tumor chemotaxis and invasion
TRAP1-directed bioenergetics has been implicated in tumor
traits (18), including tumor cell motility (19), and this possibil-
ity was next investigated. We found that Myc silencing with two
independent siRNA sequences (Fig. S6A) or pooled siRNA (Fig.
3A) potently inhibited tumor cell motility (Fig. S6A; Fig. 3A).
Quantitative analysis of time-lapse video microscopy demon-
Figure 2. Identification of TRAP1 as a Myc target gene. A, ChIP-Seq tracks of Myc accumulation at the TRAP1 promoter in P493 at three time points after
removal of Dox or neuroblastoma BE2C, Kelly, or NGP cell lines. B, ChIP of Myc accumulation at TRAP1 or NPM1 promoter in P493 cells containing a Dox-
regulated inducible Myc transgene (Dox-off system) in the presence () or absence () of Dox (top panel) or PC3 cells transfected with siCtrl or siMyc (bottom
panel). IgG, nonbinding IgG. Mean  S.D. (n  3). *, p  0.04 – 0.01; **, p  0.005. C–E, PC3 cells transfected with siCtrl or siMyc were reconstituted with TRAP1
cDNA and analyzed for OCR using an Agilent Seahorse XFe96 analyzer (C, representative tracings) and basal respiration (D) or total ATP production (E) was
quantified. Mean  S.D., **, p  0.005; ***, p  0.0001. F, reconstitution conditions are as in C, and transfected PC3 cells were analyzed by Western blotting. p,
phosphorylated. G, reconstitution conditions are as in C, and isolated mitochondrial extracts were analyzed for accumulation of detergent (CHAPS)-insoluble
SDHB (C. II, left panel) or CoxII (C. IV, right panel) by Western blotting followed by densitometric quantification of protein bands. Mean  S.D.
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strated that Myc loss suppressed the speed of cell movements
and shortened the total distance traveled by individual cells
(Fig. 3B; Fig. S6B). Consistent with these data, Myc knockdown
suppressed tumor cell invasion across Matrigel-coated inserts
(Fig. 3, C and D; Fig. S6, D and E). In reconstitution experi-
ments, re-expression of TRAP1 in Myc-silenced cells was suf-
ficient to correct the defect in tumor cell motility (Fig. 3A; Fig.
S6A), restore the speed of cell movements and the total distance
traveled by individual cells (Fig. 3B; Fig. S6B), and increase
tumor cell invasion across Matrigel to levels of control trans-
fectants (Fig. 3, C and D; Fig. S6, C and D). Biochemically, PC3
cells reconstituted with TRAP1 also exhibited phosphorylation
of cell motility kinases, Src and focal adhesion kinase (FAK),
which was suppressed by Myc knockdown (Fig. 3E).
Pharmacologic targeting of Myc–TRAP1 for cancer therapy
Analysis of neuroblastoma patient cohorts revealed that
TRAP1 expression was strongly associated with N-Myc levels
(p  1  1063–2  1096) (Fig. S7A) and correlated with
shortened overall survival (Fig. S7B), reinforcing the clinical
relevance of this pathway. To test whether this could provide an
actionable therapeutic target, we next treated P493 or neuro-
blastoma NLF or IMR cells with a mitochondria-targeted small
molecule TRAP1 antagonist, Gamitrinib (18). In these experi-
ments, Gamitrinib treatment caused concentration-dependent
dissipation of mitochondrial inner membrane potential (Fig.
S7C) and complete loss of tumor cell viability (Fig. 4A). This
response was specific because siRNA silencing of TRAP1 atten-
uated Gamitrinib-mediated cell killing, whereas reconstitution
with TRAP1 strongly increased cell death in these settings (Fig.
4B). Consistent with these data, Gamitrinib suppressed neuro-
blastoma NLF or IMR colony formation (Fig. 4, C and D) and
inhibited P493 xenograft tumor growth in immunocompro-
mised mice (Fig. 4, E and F). When analyzed in a model of
disseminated disease, systemic administration of Gamitrinib
suppressed liver metastases of PC3 cells (Fig. 4G), reducing
both the surface area and number of metastatic foci (Fig. 4H),
compared with vehicle-treated animals.
In sum, the identification of TRAP1 as a direct transcrip-
tional target of a ubiquitous oncogene, i.e. Myc (11), demon-
strates that mitochondrial reprogramming is a universal trait of
cancer, required for primary and metastatic tumor growth.
This is consistent with an expanding role of mitochondria as
tumor drivers (4), and mechanisms of intra-organelle protein
folding, oxidative bioenergetics, and ROS buffering (18) as key
requirements of cancer progression. The regulation by Myc
explains why TRAP1 is prominently overexpressed in geneti-
cally disparate malignancies, compared with normal tissues
(20), and validates its role as a tumor driver. Data from geneti-
cally engineered mouse models support this conclusion, as
transgenic expression of TRAP1 accelerated prostatic tumori-
genesis (21), whereas homozygous deletion of TRAP1 delayed
age-associated pathologies, including cancer (22). On the other
hand, the Myc–TRAP1 axis of mitochondrial reprogramming
is druggable, and selective disruption of intra-organelle protein
Figure 3. Myc–TRAP1 regulation of tumor cell motility. A, PC3 cells transfected with siCtrl or siMyc were reconstituted with TRAP1 cDNA and analyzed for
2D cell motility by time-lapse video microscopy. Each tracing corresponds to the movements of an individual cell (n  19 –20). The cutoff velocities for slow
(0.9 m/min)- or fast (	0.9 m/min)-moving cells are indicated. The siCtrl panel is the same as siCtrl in Fig. S6A. B, conditions are as in A, and PC3 cells were
analyzed for speed of cell movements (left panel) or total distance traveled by individual cells (right panel). Each symbol corresponds to an individual determi-
nation (n  38 – 41). ***, p  0.0001; ns, not significant. C and D, conditions are as in A, and transfected PC3 cells were analyzed for invasion across Matrigel-
coated inserts (C, representative images of 4
,6-diamidino-2-phenylindole–stained nuclei of invaded cells) and quantified (D). Each symbol corresponds to an
individual determination (siCtrl, n  30; siMyc, n  26; siMyc  TRAP1, n  29). The siCtrl panel is the same as siCtrl in Fig. S6C. Scale bars, 50 m. Mean  S.D.
***, p  0.0001; ns, not significant. E, conditions are as in A, and transfected PC3 cells were analyzed by Western blotting.
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folding with Gamitrinib (18) delivered potent tumor cell killing
and anticancer activity in preclinical models. This therapeutic
vulnerability may be exploited for personalized therapy of com-
mon, hard-to-treat Myc-driven cancers (16).
Experimental procedures
Cells and cell culture
Prostate adenocarcinoma PC3 or DU145 cells were obtained
from the American Type Culture Collection and maintained in
culture according to the supplier’s specifications. A human
Burkitt’s lymphoma P493-6 cell line was described previously
(23). Clones of P493 cells containing a doxycycline (Dox)-reg-
ulated Myc transgene induced after Dox removal (Dox-off
system) were as described previously (24). Neuroblastoma
SHEP21N, SHEP21-NMycER (25), and SKNAS-N-MycER (26)
cells containing a conditionally-regulated N-Myc transgene
were as described. In these cells, treatment with 50 ng/ml Dox
for 48 h suppresses N-Myc expression, whereas addition of
4-hydroxytamoxifen (4OHT, 0.5 g/ml) results in strong
N-Myc induction.
Antibodies and reagents
Antibodies to Myc and TRAP1 were purchased from Abcam
and BD Biosciences, respectively. Antibodies to AMPK,
pAMPK (Thr-172), Src, pSrc (Tyr-416), FAK, pFAK (Tyr-925
or Tyr-397), and N-Myc were from Cell Signaling Technology.
An antibody to -actin was from Sigma. Antibodies to Prx3
(Santa Cruz Biotechnology) or 2-Cys PrxSO3 (Thermo Fisher
Scientific Inc.) were used. Dox, -estradiol, and 4OHT were
purchased from Sigma. The complete chemical synthesis,
HPLC profile, and MS of mitochondria-targeted small mole-
cule Hsp90/TRAP1 antagonist Gamitrinib (GA miochondrial
matrx inhibitors) has been reported previously (19).
Plasmid and siRNA transfection
Gene knockdown experiments by small interfering RNA
(siRNA) were as described previously (19). The following
siRNA sequences were used: control; ON-TARGETplus non-
targeting siRNA pool (D-001810); human Myc-directed siRNA
(L-020010); human Myc siRNA #1 (J-003282-23); human Myc
siRNA #2 (J-003282-24); and human N-Myc directed siRNA
(L-003913-01).
Chromatin immunoprecipitation (ChIP) assay
P493 cells treated with -estradiol plus Dox for 48 h or PC3
cells transfected with control nontargeting siRNA or Myc-di-
rected siRNA for 72 h were used for ChIP experiments as
described previously (27)
TRAP1 promoter analysis
Genomic DNA sequences were downloaded from the Uni-
versity of California Santa Cruz Genome browser (http://
genome.ucsc.edu)3 (37). Putative Myc- or N-Myc– binding
sites were identified using Factorbook motif. A 1,397-bp region
of the human TRAP1 gene (1330 to 66, 1 corresponds to
the transcription start site) containing two putative Myc-bind-
ing sites (5
-Ca/gCGTG-3
) was amplified and cloned in
pGL4.15-promoterless vector upstream from a luciferase
reporter gene. For analysis of promoter activity, PC3 or P493
cells transfected with control nontargeting siRNA or Myc-di-
3 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
Figure 4. Myc–TRAP1 signaling promotes primary and metastatic tumor growth. A, P493, NLF, or IMR cells were incubated with increasing concentrations
of Gamitrinib (Gam) and analyzed for cell viability after the indicated time intervals. FU, fluorescence units. Mean  S.D. (n  3). B, IMR cells were transfected
with TRAP1-directed siRNA, reconstituted with vector or TRAP1, and analyzed for cell viability in the presence of Gamitrinib. Mean  S.D. (n  8). ***, p  0.0001.
C and D, NLF or IMR cells were treated with the indicated concentrations of Gamitrinib and analyzed for colony formation (B, representative images) and
quantified (C). Mean  S.D. (n  3). E, P493 cells were engrafted s.c. in athymic nude mice, and randomized animal groups were treated with vehicle (Veh) or
Gamitrinib (10 mg/kg/daily/i.p.) with quantification of tumor growth at the indicated time intervals. Trend lines correspond to an individual tumor. F, condi-
tions are as in E, and tumor growth in the indicated animal groups was quantified after 12 days of treatment. Mean  S.E. (n  12). **, p  0.003. G,
immunocompromised mice injected with PC3 cells into the spleen were treated with vehicle or Gamitrinib (10 mg/kg/daily/i.p.), and metastatic foci in the liver
were analyzed by H&E staining after 11 days. White circles, metastatic foci. Representative images are shown. Scale bar, 500 m. H, conditions are as in G, and
the surface area (top panel) and number (bottom panel) of liver metastases in each treatment group were quantified (top, n  156 –344; bottom, n  4 –7).
Mean  S.D.**, p  0.002; ***, p  0.0001.
EDITORS’ PICK: Myc regulation of mitochondrial protein folding
J. Biol. Chem. (2019) 294(27) 10407–10414 10411
 at T
hom
as Jefferson U
niversity on July 31, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
rected siRNA were reconstituted with 2 g of TRAP1-lucifer-
ase reporter plasmid (TRAP1-Luc), and luciferase activity was
quantified following the manufacturer’s protocol (Promega).
Global metabolomics screening
PC3 cells (2  106) were transfected with control siRNA or
Myc-directed siRNA followed by incubation with 800 l of
methanol for 30 s. The cell extract was further incubated with
550 l of Milli-Q water containing internal standards (H3304-
1002, Human Metabolome Technologies, Inc., Tsuruoka,
Japan) for 30 s and centrifuged at 2,300  g for 5 min at 4 °C.
Proteins were removed by centrifugation of an 800-l upper
aqueous layer through a Millipore 5-kDa cutoff filter at 9,100 
g for 120 min at 4 °C, and the filtrate was centrifugally concen-
trated and suspended in 50 l of Milli-Q water for capillary
electrophoresis-mass spectrometry analysis. Global metabo-
lome measurements were carried out at Human Metabolome
Technology Inc. (Tsuruoka, Japan) (28). Hierarchical cluster
analysis and principal component analysis were performed
using proprietary PeakStat and SampleStat software, respec-
tively. Detected metabolites were plotted on metabolic pathway
maps using VANTED (Visualization and Analysis of Networks
containing Experimental Data) software (29).
Focused metabolite analysis
LC-MS analysis was performed on a Thermo Fisher Scien-
tific Q Exactive HF-X mass spectrometer equipped with a HESI
II probe and coupled to a Thermo Fisher Scientific Vanquish
Horizon UHPLC system. Polar metabolites were extracted
using 80% methanol and separated at 0.2 ml/min by HILIC
chromatography at 45 °C on a ZIC-pHILIC 2.1 inner diame-
ter  150-mm column using 20 mM ammonium carbonate,
0.1% ammonium hydroxide, pH 9.2, and acetonitrile with a gra-
dient of 0 min, 85% B; 2 min, 85% B; 17 min, 20% B; 17.1 min,
85% B; and 26 min, 85% B. Relevant MS parameters were as
follows: sheath gas, 40; auxiliary gas, 10; sweep gas, 1; auxiliary
gas heater temperature, 350 °C; spray voltage, 3.5 kV for the
positive mode and 3.2 kV for the negative mode; capillary tem-
perature, 325 °C; and funnel RF level at 40. A sample pool (qual-
ity control) was generated by combining an equal volume of
each sample and analyzed using a full MS scan at the start,
middle, and end of the run sequence. For full MS analyses, data
were acquired with polarity switching at: scan range 65 to 975
m/z; 120,000 resolution; automated gain control (AGC) target
of 1E6; and maximum injection time (IT) of 100 ms. Data-de-
pendent MS/MS was performed without polarity switching; a
full MS scan was acquired as described above, followed by
MS/MS of the 10 most abundant ions at 15,000 resolution,
AGC target of 5E4, maximum IT of 50 ms, isolation width of 1.0
m/z, and stepped collision energy of 20, 40, and 60. Metabolite
identification and quantitation were performed using Com-
pound Discoverer 3.0. Metabolites were identified from a mass
list of 206 verified compounds (high confidence identifications)
as well as by searching the MS/MS data against the mzCloud
database and accepting tentative identifications with a mini-
mum score of 50.
Mitochondrial protein folding
Protein lysates were prepared in RIPA buffer, and equal
amounts of protein lysates were separated by SDS-gel electro-
phoresis as described previously (30). Changes in mitochon-
drial protein folding were assessed at increasing detergent
(CHAPS) concentrations (0 –2.5%) as described previously
(17).
Mitochondrial bioenergetics
PC3 cells were analyzed for changes in oxidative phosphory-
lation complex activity using Abcam reagents (complex I, cat-
alog no. ab109721; complex II, catalog no. ab109908; complex
III, catalog no. ab109909; complex IV, catalog no. ab109905), as
described previously (17). Complex V activity was quantified
using Cayman reagent catalog no. 701000. OCR, ECAR, and
ATP production were quantified using an Agilent Seahorse
XFe96 analyzer (Agilent Technologies, Wilmington, DE).
Changes in mitochondrial ROS production (MitoSox Red) and
inner membrane potential (tetramethylrhodamine, ethyl ester)
were assessed as described previously (31). Assays for glucose
(eEnzyme CAG005) and lactate (Abcam Ab65331) production
and oxygen consumption (ENZO Life Sciences ENZ-51045-1)
were used.
Cell viability assay and colony formation
Changes in cell viability in control or Gamitrinib (0 –15 M)-
treated P493, NLF, or IMR cultures were quantified by a fluo-
rogenic Alamar Blue dye, as described previously (32). NLF and
IMR neuroblastoma cells were treated with vehicle or Gami-
trinib (0 –10 M) and plated at 200 cells per condition, and
macroscopically-visible colonies stained with 0.5% w/v crystal
violet/methanol were manually counted after 14 days.
Tumor cell motility and invasion
PC3 cells transfected with control nontargeting siRNA or
Myc-directed siRNA were analyzed for 2D motility in 4-well
Ph chambers (Ibidi) by time-lapse video microscopy over
10 h, as described previously (30). Tracking data were exported
into the Chemotaxis and Migration Tool version 2.0 (Ibidi) for
graphing and calculation of mean and standard deviation of
speed accumulated distance of movement. Tumor cell invasion
was determined using growth factor reduced Matrigel-coated 8
m PET Transwell chambers (Corning), as described previ-
ously (30).
Bioinformatics analysis
Differential expressions for metabolomics data were tested
using Student’s t test, and p values were corrected for multiple
testing using Benjamini-Hochberg method. Metabolites that
passed a false discovery rate 5% cutoff were considered sig-
nificant. Overlap between the two metabolomics experiments
was performed using KEGG and HMDB identifications. All
known interactions between overlapped metabolites were
derived from the Ingenuity Knowledge Base. CHIP-seq data for
c-Myc in P493 Burkitt’s lymphoma cells at three independent
time points after Dox addition were derived from NCBI GEO
database set GSE36354 (24). CHIP-seq analysis of N-Myc dis-
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tribution in neuroblastoma BE2C, Kelly, and NGP cells was
from GEO database set GSE36354 (33). Data were aligned using
bowtie (34) against hg19 genome version and analyzed using
the HOMER (35) algorithm to generate bigwig files used for
visualizing CHIP-seq tracks in the UCSC browser.
Animal studies
Studies involving mice were carried out in accordance with
the Guide for the Care and Use of Laboratory Animals and
approved by the Institutional Animal Care and Use Committee
(IACUC) of The Wistar Institute (protocol nos. 112625 and
112610). P493 cells (2  107) were injected s.c. in athymic nude
mice. Once tumors reached 100 mm3 in volume, animals were
randomized into two groups to receive 20% Cremophor (vehi-
cle) or Gamitrinib (10 mg/kg) daily i.p. for 10 days. For a liver
metastasis model, PC3 cells (1  106) were injected into the
spleen of SCID/beige mice, and randomized animal groups
were treated with vehicle or Gamitrinib for 11 days before his-
tological quantification of liver metastases, as described previ-
ously (36).
Statistical analysis
Data are expressed as means  S.D. of multiple independent
experiments or replicates of representative experiments out of
a minimum of two or three independent determinations. Two-
tailed Student’s t test was used for two-group comparative anal-
yses. Statistical analyses were performed using the GraphPad
software package (Prism 6.0). A p value of 0.05 was consid-
ered as statistically significant.
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